Delcath Systems (NASDAQ:DCTH) Trading 1.6% Higher

Delcath Systems, Inc. (NASDAQ:DCTH)’s stock price traded up 1.6% during mid-day trading on Tuesday . The stock traded as high as $5.72 and last traded at $5.60. 220,934 shares traded hands during mid-day trading, a decline of 2% from the average session volume of 225,808 shares. The stock had previously closed at $5.51.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. HC Wainwright upped their target price on shares of Delcath Systems from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, March 27th. StockNews.com raised shares of Delcath Systems to a “sell” rating in a research note on Wednesday, March 27th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Delcath Systems has a consensus rating of “Moderate Buy” and an average target price of $18.50.

Delcath Systems Price Performance

The stock has a market capitalization of $142.46 million, a P/E ratio of -1.89 and a beta of 0.53. The firm’s 50 day moving average price is $4.51 and its 200 day moving average price is $3.94.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings data on Tuesday, March 26th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.19. The firm had revenue of $0.54 million during the quarter, compared to the consensus estimate of $0.48 million. Delcath Systems had a negative net margin of 2,308.86% and a negative return on equity of 563.60%. During the same period in the prior year, the firm posted ($0.86) earnings per share. On average, equities research analysts forecast that Delcath Systems, Inc. will post -1.45 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Gil Aharon purchased 26,882 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The stock was bought at an average cost of $3.72 per share, with a total value of $100,001.04. Following the completion of the purchase, the director now directly owns 1,069,710 shares in the company, valued at $3,979,321.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 17.94% of the stock is owned by insiders.

Institutional Investors Weigh In On Delcath Systems

Institutional investors have recently made changes to their positions in the company. Levin Capital Strategies L.P. purchased a new stake in Delcath Systems in the third quarter worth approximately $162,000. Vivo Capital LLC raised its position in Delcath Systems by 57.4% in the third quarter. Vivo Capital LLC now owns 1,855,191 shares of the company’s stock worth $7,514,000 after acquiring an additional 676,404 shares during the period. Stonepine Capital Management LLC raised its position in Delcath Systems by 81.2% in the third quarter. Stonepine Capital Management LLC now owns 686,240 shares of the company’s stock worth $2,779,000 after acquiring an additional 307,453 shares during the period. Armistice Capital LLC bought a new position in Delcath Systems in the third quarter worth approximately $664,000. Finally, WealthPlan Investment Management LLC bought a new stake in shares of Delcath Systems during the 4th quarter valued at $73,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.